Journal ArticleDOI
Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study
Tetsuya Hosaka,Fumitaka Suzuki,Masahiro Kobayashi,Yuya Seko,Yusuke Kawamura,Hitomi Sezaki,Norio Akuta,Yoshiyuki Suzuki,Satoshi Saitoh,Yasuji Arase,Kenji Ikeda,Mariko Kobayashi,Hiromitsu Kumada +12 more
Reads0
Chats0
TLDR
It is suggested that both direct antiviral potential and host immune response are needed to achieve HBsAg clearance by NA therapy, and Viral genotype strongly influenced HBs Ag clearance during NA therapy.Abstract:
Clearance of hepatitis B surface antigen (HBsAg) is considered the ultimate goal in chronic hepatitis B treatment. One treatment option is long-term nucleot(s)ide analog (NA) therapy. We followed a group of long-term NA therapy patients to evaluate the efficacy of this treatment in promoting clearance and longitudinal declines of HBsAg. The study included 791 NA therapy patients who received lamivudine as their first drug. At the baseline, 442 patients were hepatitis B e antigen (HBeAg)+ and 349 were HBeAg−. All analyses were performed after separating the HBeAg+ and HBeAg− cohorts. Cox proportional hazards models were used to determine which factors were associated with HBsAg clearance. HBsAg clearance was observed in 18 (4.1 %) of the HBeAg+ patients and 20 (5.7 %) of the HBeAg− patients at baseline, giving seroclearance rates of 6.4 and 6.9 %, respectively, over the nine-year study period. HBsAg clearance was influenced by several independent factors that varied according to HBeAg cohort. For HBeAg+ patients, these included previous interferon therapy, infection with hepatitis B virus (HBV) genotype A, a ≥0.5 log IU/mL decline in HBsAg level within six months, and clearance of HBeAg at six months. For HBeAg− patients, these included infection with HBV genotype A, decline in HBsAg at six months, and a baseline HBsAg level of <730 IU/mL. This study suggests that both direct antiviral potential and host immune response are needed to achieve HBsAg clearance by NA therapy. Viral genotype strongly influenced HBsAg clearance during NA therapy.read more
Citations
More filters
Journal Article
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B in China
TL;DR: In Chinese patients with HBeAg-positive chronic hepatitis B,52 weeks of ADV treatment resulted in significant virologic, biochemical improvement with good safety profile and no evidence of the emer- gence of adefoyir-resistant HBV polymerase mutations was found.
Journal ArticleDOI
Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis
Yee Hui Yeo,Hsiu J. Ho,Hwai I. Yang,Tai-Chung Tseng,Tetsuya Hosaka,Huy N. Trinh,Min Sun Kwak,Young Min Park,James Fung,Maria Buti,Manuel J. Rodriguez,Sombat Treeprasertsuk,Carmen Monica Preda,Teerapat Ungtrakul,Phunchai Charatcharoenwitthaya,Xiangyong Li,Jiayi Li,Jian Zhang,Michael H. Le,Bin Wei,Biyao Zou,An Le,Donghak Jeong,Nicholas Chien,Leslie Y. Kam,Chiao-Chin Lee,Mar Riveiro-Barciela,Doina Istratescu,Tassanee Sriprayoon,Yutian Chong,Tawesak Tanwandee,Mariko Kobayashi,Fumitaka Suzuki,Man-Fung Yuen,Hyo Suk Lee,Jia-Horng Kao,Anna S. Lok,Chun Ying Wu,Chun Ying Wu,Mindie H. Nguyen +39 more
TL;DR: A systematic review and meta-analysis of cohort studies found a low rate of HBsAg seroclearance in untreated and treated patients (pooled annual rate, approximately 1%), which occurred mainly in patients with less active disease.
Journal ArticleDOI
The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment.
Chien-Hung Chen,Sheng-Nan Lu,Chao-Hung Hung,Jing-Houng Wang,Tsung-Hui Hu,Chi-Sin Changchien,Chuan-Mo Lee +6 more
TL;DR: Serum HBsAg level at the end of treatment is a useful predictor to guide the timing of stopping lamivudine treatment in chronic hepatitis B patients.
Journal ArticleDOI
A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea
Seung Up Kim,Yeon Seok Seo,Han Ah Lee,Mi Na Kim,Yu Rim Lee,Hye Won Lee,Jun Yong Park,Do Young Kim,Sang Hoon Ahn,Kwang Hyub Han,Seong Gyu Hwang,Kyu Sung Rim,Soon Ho Um,Won Young Tak,Young Oh Kweon,Beom Kyung Kim,Soo-Young Park +16 more
TL;DR: The overall prognosis in terms of HCC and death or OLT was statistically not different between the ETV and TDF groups, and these findings were consistently reproduced in patients with compensated cirrhosis.
Journal ArticleDOI
HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.
TL;DR: Monitoring serum HBsAg levels in chronic hepatitis B (CHB) patients during treatment may provide significant complementary information to HBV DNA measurements, which could help predict treatment outcome.
References
More filters
Journal ArticleDOI
Hepatitis B virus infection [1] (multiple letters)
Journal ArticleDOI
Hepatitis B virus infection.
TL;DR: This review addresses many aspects of HBV infection, including the role of the immune system in determining the outcome of clinical infection, recent developments in molecular studies of the virus, and new treatments capable of eradicating chronic infection.
Journal ArticleDOI
Hepatitis B Virus Infection — Natural History and Clinical Consequences
Don Ganem,Alfred M. Prince +1 more
TL;DR: The structure and replication cycle of hepatitis B virus is examined and the natural history of primary infection, the mechanisms of clearance of the virus, and reasons for persistent infection are discussed.
Journal ArticleDOI
A One-Year Trial of Lamivudine for Chronic Hepatitis B
Ching-Lung Lai,R.-N. Chien,N. W. Y. Leung,Ting-Tsung Chang,R. Guan,D.-I. Tai,K.-Y. Ng,P.-C. Wu,Julie C. Dent,J. Barber,S. L. Stephenson,D. F. Gray +11 more
TL;DR: In a one-year study, lamivudine was associated with substantial histologic improvement in many patients with chronic hepatitis B, and a daily dose of 100 mg was more effective than a daily doses of 25 mg.
Journal ArticleDOI
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
Ting-Tsung Chang,Robert G. Gish,Robert A. de Man,Adrián Gadano,Jose D. Sollano,You Chen Chao,Anna S. Lok,Kwang Hyub Han,Zachary Goodman,J. Zhu,Anne Cross,Deborah DeHertogh,R B Wilber,Richard J. Colonno,David Apelian +14 more
TL;DR: Among patients with HBeAg-positive chronic hepatitis B, the rates of histologic, virologic, and biochemical improvement are significantly higher with entecavir than with lamivudine, and the safety profile of the two agents is similar.
Related Papers (5)
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.
Shiv Kumar Sarin,Manoj Kumar,George K. K. Lau,Zaigham Abbas,Henry Lik-Yuen Chan,Chien-Jen Chen,Ding-Shinn Chen,Huey-Ling Chen,Pei-Jer Chen,Rong-Nan Chien,Abdul Kadir Dokmeci,Edward Gane,J L Hou,Wasim Jafri,Jidong Jia,J. H. Kim,Ching-Lung Lai,Hon Cheung Lee,Seng Gee Lim,Chun-Jen Liu,Stephen Locarnini,M. Al Mahtab,Rosmawati Mohamed,Masao Omata,Jun Yong Park,Teerha Piratvisuth,Barjesh Chander Sharma,Jose D. Sollano,Fu-Sheng Wang,Lai Wei,Man-Fung Yuen,Shusen Zheng,Jia-Horng Kao +32 more
Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
E. Jenny Heathcote,Patrick Marcellin,Maria Buti,Edward Gane,Robert A. de Man,Zahary Krastev,George Germanidis,Samuel S. Lee,Robert Flisiak,Kelly Kaita,Michael P. Manns,Iskren Kotzev,Konstantin Tchernev,Peter Buggisch,Frank Weilert,Oya Ovunc Kurdas,Mitchell L. Shiffman,Huy N. Trinh,Selim Gürel,Andrea Snow–Lampart,Katyna Borroto–Esoda,Elsa Mondou,J. Anderson,Jeff Sorbel,Franck Rousseau +24 more